Last $11.63 USD
Change Today -0.51 / -4.20%
Volume 5.6M
ACHN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Open
$11.44
Previous Close
$12.14
Day High
$11.88
Day Low
$11.32
52 Week High
12/22/14 - $16.87
52 Week Low
05/7/14 - $2.45
Market Cap
1.3B
Average Volume 10 Days
4.7M
EPS TTM
$-0.63
Shares Outstanding
112.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHILLION PHARMACEUTICALS (ACHN)

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

61 Employees
Last Reported Date: 03/7/14
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $326.4K
Chief Compliance Officer and Executive Vice P...
Total Annual Compensation: $334.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $313.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $256.7K
Compensation as of Fiscal Year 2013.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc. Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment with ACH-3102

Achillion Pharmaceuticals, Inc. announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. 100% of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load. This ongoing study is a Phase 2 open-label, randomized, partial-crossover study to evaluate the efficacy, safety, and tolerability of eight- and six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, once daily, in treatment-naïve genotype 1 HCV-infected patients. Initially, eighteen patients were enrolled, including six observational patients, into an eight-week treatment cohort. Following the achievement of 100% SVR12 (12/12) in the eight-week cohort, the six-week treatment cohort was initiated. In all, eighteen patients were enrolled, including twelve active and six observational patients. Mean baseline HCV RNA viral load was 10 million (7 log10) IU/ml, range 2 million (6.23 log10) – 97 million (7.99 log10) IU/ml, including seven patients with baseline HCV RNA viral load exceeding 6 million (6.78 log10) IU/ml. Of the 12 active patients enrolled, seven patients were genotype 1a and five were genotype 1b. Twelve weeks after the completion of therapy, 100% (12/12) achieved SVR12, independent of baseline viral load, gender, and IL28B status, in the six-week treatment arm. Additionally, 100% of patients (12/12) in the eight-week treatment duration arm have achieved SVR24. The combination of ACH-3102 and sofosbuvir was well-tolerated with no serious adverse events, no discontinuations due to adverse events, and no clinically significant laboratory or ECG abnormalities.

Achillion Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:55 AM

Achillion Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:55 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Milind S. Deshpande, Chief Executive Officer, President and Director.

Achillion Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM

Achillion Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Milind S. Deshpande, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $11.63 USD -0.51

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,424 GBp -8.00
Bavarian Nordic A/S kr286.00 DKK +74.50
Bayer AG €132.79 EUR +1.28
Chimerix Inc $40.74 USD +0.25
Emergent Biosolutions Inc $29.48 USD +0.61
View Industry Companies
 

Industry Analysis

ACHN

Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit www.achillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.